Alivus Life Sciences share price
NSE: ALIVUSBSE: 543322Pharmaceuticals & BiotechnologySmall Cap
Alivus Life Sciences Limited · Formerly Glenmark Life Sciences · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2021 · Issue price ₹720
Last close ₹1,399.40up ₹55.80 (4.15%)BSE ₹1,400.50
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,343.60.
28 Oct: open ₹1,343.60, high ₹1,405.10, low ₹1,330.40
52-week range of traded prices to 28 Oct 2026
₹819.00Low, 22 Jan 2026₹1,493.80High, 31 Aug 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹17,181 Cr502nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 28.49
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.16
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.36%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 19.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 22.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,86,82356.9% delivered
About Alivus Life Sciences
Alivus Life Sciences develops and makes active pharmaceutical ingredients (APIs), the chemical compounds that give a medicine its effect, mainly for long-term (chronic) treatments.1 It sells them to generic and specialty drug makers in the US, Europe, Japan, Korea, Taiwan, Canada, Latin America and India.1 It also develops and manufactures ingredients under contract for innovator and specialty drug companies.2
The company reports a single business segment, APIs, and runs it as a generic API business and a contract development and manufacturing (CDMO) business.34 Its APIs include Amiodarone and Ezetimibe for heart disease, Lithium Carbonate and Oxcarbazepine for nervous system disorders, Mirabegron and Solifenacin for urology, Etoricoxib for pain, and Dapagliflozin and Sitagliptin for diabetes.5 It makes them at 4 plants, in Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra, and runs R&D centres at Mahape in Navi Mumbai, Ankleshwar and Dahej.567
It was incorporated on 23 Jun 2011.8 It was carved out of Glenmark Pharmaceuticals as an independent company and listed on the stock exchanges through an initial public offering (IPO).9 Nirma Limited, which bought a 75% holding from Glenmark Pharmaceuticals, is its promoter and held 74.87% of its shares at 31 Mar 2026.1011
Alivus Life Sciences key points
Results
- In the quarter to Jun 2026, revenue from operations rose 6.4% from a year earlier to ₹640 crore, EBITDA (earnings before interest, tax, depreciation and amortisation) rose 29.1% to ₹234 crore, a 36.6% margin, and profit after tax was ₹160 crore.12
- In the year to Mar 2026, revenue from operations rose 6.9% to ₹25,518.32 million and EBITDA was ₹8,577 million, against ₹7,172 million a year earlier, at an EBITDA margin of 33.6%, which the company calls its highest ever.131415
- Net profit for the year to Mar 2026 was ₹5,644.83 million, up from ₹4,856.27 million a year earlier.16
- In the quarter to Jun 2026 the company generated free cash flow (cash left after running costs and capital spending) of ₹901 million; its cash, including short-term investments, was ₹8,802 million at 30 Jun 2026.17
Business segments
- Generic API. Generic API revenue grew 7.4% from a year earlier in the quarter to Jun 2026, despite lower sales to Glenmark Pharmaceuticals.1819
- CDMO. Revenue from contract development and manufacturing (CDMO) grew 18% in the year to Mar 2026, taking the business to 6.6% of the company's overall portfolio and grew 3.8% from a year earlier in the quarter to Jun 2026.2021
Revenue mix
- Sales to Glenmark Pharmaceuticals, which buys more than 50 of its products, fell 52.6% from a year earlier in the quarter to Jun 2026, to 11.3% of revenue from 25.4%, which the company attributes to inventory rationalisation (lower stock holding).222324
- Sales to customers other than Glenmark Pharmaceuticals grew 26.5% in the quarter to Jun 2026; in the year to Mar 2026 they grew 13% and made up 71% of revenue.2526
Plants and capacity
- Installed capacity by plant, in kilolitres (KL)2930The plants produced 888 metric tonnes (MT) of APIs in the year to Mar 2026.
Item quarter to Jun 2026 Ankleshwar, Gujarat 950.2 KL Dahej, Gujarat 399.9 KL Mohol, Maharashtra 49.1 KL Kurkumbh, Maharashtra 24.6 KL - On its earnings call of 31 Jul 2026, the company said its new Solapur plant, after a slight delay, is expected to be operational early in the quarter to Dec 2026.31
- In its presentation of 30 Jul 2026, the company said it plans to add about 350 KL at Solapur and about 160 KL at Dahej in the quarter to Dec 2026, and about 115 KL at Solapur in the quarter to Mar 2027.3233
- The company stated in its annual report for the year to Mar 2026 that it plans to raise total reactor capacity from 1,424 KL to 2,690 KL by the year to Mar 2029.34
Research and development
- Research and development spending was ₹24 crore in the quarter to Jun 2026, 3.7% of sales, after ₹925 million, 3.6% of sales, in the year to Mar 2026.3536
- By 30 Jun 2026 the company had filed 617 drug master files and certificates of suitability (dossiers that let drug makers use its APIs in their medicines).3738
- Its high-potency API portfolio (very potent ingredients that need sealed handling) has 29 products in development: 13 validated, 7 in advanced development and 9 in lab development.39
What the company expects
- On its earnings call of 31 Jul 2026, the company said it expects revenue to grow 10% to 12% in the year to Mar 2027, weighted towards the second half, with EBITDA margins in the 30% to 32% range.40
- On its earnings call of 31 Jul 2026, the company said it expects sales to Glenmark Pharmaceuticals to be roughly flat in the year to Mar 2027, weighted to the second half.41
- On its earnings call of 31 Jul 2026, the company said it expects capital spending of about ₹540 crore in the year to Mar 2027; its annual report says this includes carryover commitments and is funded entirely through internal accruals (retained profits).4243
Recent events
- On 7 Oct 2026, the company said it had bought a 9.21% stake in Torrent Urja 19 Private Limited, a special purpose vehicle set up for solar and other renewable energy projects, for ₹14.04 crore, to qualify as a captive user of its power.4445
- On 15 Sep 2026, the company set up a wholly owned subsidiary, Alivus Life Sciences Do Brasil Ltda., in Sao Paulo, Brazil.46
- On 18 Aug 2026, the board approved buying 76% of IQGenX Pharma Private Limited, a custom research organisation developing oral solids, sterile injectables and ophthalmic (eye) formulations, for about ₹9.12 crore, with completion expected by 6 Dec 2026 or a date agreed, subject to conditions.474849
Last updated
All 49 sources, each with its page
- 1. Annual report, 11 Aug 2026, page 8
- 2. Annual report, 11 Aug 2026, page 18
- 3. Annual report, 11 Aug 2026, page 122
- 4. Annual report, 11 Aug 2026, page 37
- 5. Annual report, 11 Aug 2026, page 9
- 6. Annual report, 11 Aug 2026, page 17
- 7. Annual report, 11 Aug 2026, page 20
- 8. Annual report, 11 Aug 2026, page 53
- 9. Annual report, 11 Aug 2026, page 10
- 10. Annual report, 11 Aug 2026, page 48
- 11. Annual report, 11 Aug 2026, page 114
- 12. Earnings call, 31 Jul 2026, page 5
- 13. Annual report, 11 Aug 2026, page 42
- 14. Annual report, 11 Aug 2026, page 4
- 15. Annual report, 11 Aug 2026, page 7
- 16. Annual report, 11 Aug 2026, page 43
- 17. Investor presentation, 30 Jul 2026, page 5
- 18. Investor presentation, 30 Jul 2026, page 11
- 19. Investor presentation, 30 Jul 2026, page 5
- 20. Annual report, 11 Aug 2026, page 8
- 21. Earnings call, 31 Jul 2026, page 4
- 22. Investor presentation, 30 Jul 2026, page 12
- 23. Earnings call, 31 Jul 2026, page 6
- 24. Investor presentation, 30 Jul 2026, page 5
- 25. Earnings call, 31 Jul 2026, page 3
- 26. Annual report, 11 Aug 2026, page 7
- 27. Annual report, 11 Aug 2026, page 122
- 28. Investor presentation, 30 Jul 2026, page 13
- 29. Investor presentation, 30 Jul 2026, page 17
- 30. Annual report, 11 Aug 2026, page 17
- 31. Earnings call, 31 Jul 2026, page 4
- 32. Investor presentation, 30 Jul 2026, page 20
- 33. Annual report, 11 Aug 2026, page 19
- 34. Annual report, 11 Aug 2026, page 15
- 35. Earnings call, 31 Jul 2026, page 5
- 36. Annual report, 11 Aug 2026, page 41
- 37. Investor presentation, 30 Jul 2026, page 16
- 38. Investor presentation, 30 Jul 2026, page 15
- 39. Earnings call, 31 Jul 2026, page 4
- 40. Earnings call, 31 Jul 2026, page 4
- 41. Earnings call, 31 Jul 2026, page 4
- 42. Earnings call, 31 Jul 2026, page 5
- 43. Annual report, 11 Aug 2026, page 19
- 44. Exchange filing, 7 Oct 2026, page 2
- 45. Exchange filing, 7 Oct 2026, page 3
- 46. Exchange filing, 16 Sep 2026, page 1
- 47. Exchange filing, 18 Aug 2026, page 1
- 48. Exchange filing, 18 Aug 2026, page 2
- 49. Exchange filing, 18 Aug 2026, page 2
Results
Standalone; ₹ crore.Alivus Life Sciences quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +7.9%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +21.7%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹640 Crdown 7.07%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹160 Crdown 1.59%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 25.0%
Revenue by quarter
Peak revenue ₹689 Cr, quarter to Mar 2026; lowest ₹507 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 |
| Net profit | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 |
| Net margin | 18.8% | 21.3% | 21.8% | 20.2% | 22.1% | 22.3% | 23.6% | 25.0% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹2,552 Crup 6.91%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹564 Crup 16.24%
- Net margin
- 22.1%
Revenue by year
Peak revenue ₹2,552 Cr, year to Mar 2026; lowest ₹2,123 Cr, year to Mar 2022
Net profit by year, a loss in red
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 |
| Net profit | 419 | 467 | 471 | 486 | 564 |
| Net margin | 19.7% | 21.6% | 20.6% | 20.3% | 22.1% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Active Pharmaceutical Ingredient (API), which carries all its revenue.
Valuation
Today, against the company's own history.Alivus Life Sciences PE ratio and valuation
Price to earnings
At or below today's level on 87% of 1,122 trading days since Apr 2022.
LowestHighest
Its median20.99Industry median27.98
Price to book
At or below today's level on 91% of 1,230 trading days since Nov 2021.
LowestHighest
Its median3.81Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 19% of 1,239 trading days over the last 5 years.
LowestHighest
Its median2.14%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −9.5% | +16.0% | −22.5% | 0.5% |
| 3 years | +36.6% | +6.5% | +27.1% | 1.3% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
13 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 3 of the 7 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 13 funds holding Alivus Life Sciences
- AddedAdded. Funds that held more shares than at the end of the month before.
- 3
- CutCut. Funds that held fewer shares than at the end of the month before.
- 4
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 6
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 7
| Fund | |||
|---|---|---|---|
 quant Small Cap Fundquant Mutual Fund | 22,24,804 | 0.86% | ₹306.9 Cr |
 Old Bridge Focused FundOld Bridge Mutual Fund | 13,19,512 | 4.01% | ₹182.0 Cr |
| quant Flexi Cap Fundquant Mutual Fund | 10,88,244 | 2.05% | ₹150.1 Cr |
 Bandhan Large & Mid Cap FundBandhan Mutual Fund | 9,08,641 | 0.61% | ₹125.3 Cr |
 ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 4,80,427 | 0.97% | ₹66.3 Cr |
| quant Healthcare Fundquant Mutual Fund | 1,91,248 | 6.21% | ₹26.4 Cr |
 Helios Small Cap FundHelios Mutual Fund | 1,26,517 | 0.93% | ₹17.5 Cr |
 Quantum Small Cap FundQuantum Mutual Fund | 49,463 | 2.61% | ₹6.82 Cr |
| Bandhan Healthcare FundBandhan Mutual Fund | 27,172 | 1.15% | ₹3.75 Cr |
 Unifi Flexi Cap FundUnifi Mutual Fund | 20,000 | 1.16% | ₹2.76 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Alivus Life Sciences insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Alivus Life Sciences competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Alivus Life Sciences in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Shilpa MedicareSHILPAMED | 18,228 | 61.31 | 7.03 | +27.9% | +167.6% | 12.0% | 10.9% | 0.06% |
 Cohance LifesciencesCOHANCE | 18,214 | 171.45 | 4.66 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
 Onesource Specialty PharmaONESOURCE | 18,091 | – | 3.06 | +10.7% | −103.9% | 0.0% | 1.5% | 0.00% |
 Caplin Point LaboratoriesCAPLIPOINT | 17,960 | 26.99 | 5.01 | +15.0% | +17.7% | 20.7% | 19.8% | 0.34% |
 PfizerPFIZER | 17,084 | 23.24 | 4.06 | +10.7% | −9.1% | 17.5% | 21.0% | 2.01% |
 Eris LifesciencesERIS | 16,307 | 23.05 | 3.93 | +11.1% | +70.2% | 19.6% | 13.4% | 0.61% |
 AstraZeneca Pharma IndiaASTRAZEN | 15,593 | 91.93 | 17.87 | +31.1% | −7.5% | 20.6% | 24.4% | 0.58% |
 Natco PharmaNATCOPHARM | 15,556 | 13.59 | – | −20.7% | −32.6% | 13.6% | 8.6% | 0.57% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Alivus Life Sciences dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹22.50 a share, year to Mar 2024.
| Ex-date | Type | Per share |
|---|---|---|
| 1 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹5.00 |
| 1 Sep 2025 | Final | ₹5.00 |
| 17 Oct 2023 | Interim | ₹22.50 |
| 24 Mar 2023 | Interim | ₹21.00 |
| 15 Sep 2022 | Final | ₹10.50 |
| 22 Nov 2021 | Interim | ₹10.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Alivus Life Sciences announcements
Oct 2026
22 Oct · Analysts
9 Oct
7 Oct · General Updates
Sep 2026
16 Sep · General Updates
11 Sep · Analysts
Alivus Life Sciences share price by year
Each calendar year to 2025.Alivus Life Sciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 916.60 | −6.8% | 1,237.15 | 860.05 |
| 2024 | 983.45 | +49.7% | 1,310.90 | 655.20 |
| 2023 | 657.05 | +56.4% | 671.55 | 374.55 |
| 2022 | 420.15 | −33.4% | 623.30 | 376.55 |
| 2021 | 631.05 | – | 765.10 | 594.05 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2021 is from its first session, 6 Aug 2021.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,256.00 | 1,357.80 | 1,256.00 | 1,343.60 | 1,322.98 | 1,06,779 | 60.9% |
| 26 Oct 2026 | 1,229.30 | 1,276.80 | 1,222.00 | 1,262.00 | 1,257.46 | 42,476 | 43.1% |
| 23 Oct 2026 | 1,271.90 | 1,295.80 | 1,208.10 | 1,250.60 | 1,241.40 | 87,236 | 55.9% |
| 22 Oct 2026 | 1,259.90 | 1,280.00 | 1,242.70 | 1,269.00 | 1,261.85 | 47,016 | 45.4% |
| 21 Oct 2026 | 1,268.60 | 1,288.90 | 1,219.40 | 1,257.90 | 1,245.04 | 97,843 | 53.4% |
| 19 Oct 2026 | 1,309.50 | 1,324.90 | 1,256.20 | 1,268.60 | 1,271.08 | 1,36,164 | 58.4% |
| 16 Oct 2026 | 1,340.10 | 1,340.70 | 1,306.10 | 1,309.50 | 1,321.97 | 35,946 | 52.7% |
| 15 Oct 2026 | 1,355.00 | 1,357.40 | 1,325.70 | 1,341.80 | 1,341.00 | 51,716 | 64.5% |
| 14 Oct 2026 | 1,344.40 | 1,357.40 | 1,328.80 | 1,348.00 | 1,346.42 | 80,940 | 60.2% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- ALIVUS
- BSE code
- 543322
- ISIN
- INE03Q201024
- Industry
- Pharmaceuticals & Biotechnology
- Former symbols
- GLS
- Website
- www.glenmarklifesciences.com
- CIN
- L74900PN2011PLC139963
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2011
- Registered office
- Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur 413213, Maharashtra
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments